Abbott Labs Says Study Favors Depakote Over Zyprexa

16 декабря, 2002
Dow Jones Business News via Dow Jones ABBOTT PARK, Ill. --Abbott Laboratories said its Depakote treatment for bipolar disorder has fewer side effects than Eli Lilly & Co.'s antipsychotic drug Zyprexa. Dow Jones Online News via NewsEdge Corporation : Dow Jones Business News via Dow Jones ABBOTT PARK, Ill. (Dow Jones)--Abbott Laboratories (ABT) said its Depakote treatment for bipolar disorder has fewer side effects than Eli Lilly & Co.'s (LLY) antipsychotic drug Zyprexa. In a press release Monday, Abbott said a study of 120 patients showed that the two drugs have similar efficacy in treating acute mania, but Depakote users reported fewer instances of weight gain, drowsiness, runny nose, speech disorder and swelling. Depakote, approved by the Food and Drug Administration in 1995, is the most prescribed treatment for mania, Abbott said. New York Stock Exchange-listed shares of Abbott recently traded at $39.95, down 53 cents, or 1.3%, on composite volume of 701,600 shares. Average daily volume is 4.5 million shares. -Kara Wetzel; Dow Jones Newswires; 201-938-5388 (END) Dow Jones Newswires 12-16-02 1105ET - - 11 05 AM EST 12-16-02 DJONviaNewsEdge <> << Copyright ©2002 Dow Jones and Company, Inc. >>
Разделы
Новости